Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 432 entries
Sorted by: Best Match Show Resources per page
Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Current oncology (Toronto, Ont.)

Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, Guay MP.
PMID: 25089112
Curr Oncol. 2014 Aug;21(4):e630-41. doi: 10.3747/co.21.1966.

BACKGROUND: Although antineoplastic agents are critical in the treatment of cancer, they can potentially cause hypersensitivity reactions that can have serious consequences. When such a reaction occurs, clinicians can either continue the treatment, at the risk of causing a...

Cite
Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-41doi: 10.3747/co.21.1966.
Boulanger, J., Boursiquot, J. N., Cournoyer, G., Lemieux, J., Masse, M. S., Almanric, K., Guay, M. P. (2014). Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Current oncology (Toronto, Ont.), 21(4), e630-41. https://doi.org/10.3747/co.21.1966
Boulanger, J, et al. "Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations." Current oncology (Toronto, Ont.) vol. 21,4 (2014): e630-41. doi: https://doi.org/10.3747/co.21.1966
Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, Guay MP. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014 Aug;21(4):e630-41. doi: 10.3747/co.21.1966. PMID: 25089112; PMCID: PMC4117628.
Copy Download .nbib Format: NLM
Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Resnik E, Lefevre CA.
PMID: 11240821
Int J Gynecol Cancer. 1999 Nov;9(6):512-514. doi: 10.1046/j.1525-1438.1999.99065.x.

Resnik E, LeFevre CA. Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Pseudomembranous colitis is commonly associated with the use of antibiotics. Some antineoplastic agents even without associated antibiotic use can predispose patients to developing infection with...

Cite
Resnik E, Lefevre CA. Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer. 1999;9(6):512-514doi: 10.1046/j.1525-1438.1999.99065.x.
Resnik, E., & Lefevre, C. A. (1999). Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 9(6), 512-514. https://doi.org/10.1046/j.1525-1438.1999.99065.x
Resnik, E., and Lefevre, C. A.. "Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 9,6 (1999): 512-514. doi: https://doi.org/10.1046/j.1525-1438.1999.99065.x
Resnik E, Lefevre CA. Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer. 1999 Nov;9(6):512-514. doi: 10.1046/j.1525-1438.1999.99065.x. PMID: 11240821.
Copy Download .nbib Format: NLM
Synthesis and cytotoxicity of cyanoborane adducts of n6-benzoyladenine and 6-triphenylphosphonylpurine.

Metal-based drugs

Scarlett TC, Durham RW, Hall IH, Crosswicks RJ, Berkowitz JD, Burnham BS.
PMID: 18475422
Met Based Drugs. 2002;9(1):19-32. doi: 10.1155/MBD.2002.19.

N6-Benzoyladenine-cyanoborane (2), and 6-triphenylphosphonylpurine-cyanoborane (3) were selected for investigation of cytotoxicity in murine and human tumor cell lines, effects on human HL-60 leukemic metabolism and DNA strand scission to determine the feasibility of these compounds as clinical antineoplastic agents....

Cite
Scarlett TC, Durham RW, Hall IH, et al. Synthesis and cytotoxicity of cyanoborane adducts of n6-benzoyladenine and 6-triphenylphosphonylpurine. Met Based Drugs. 2002;9(1):19-32doi: 10.1155/MBD.2002.19.
Scarlett, T. C., Durham, R. W., Hall, I. H., Crosswicks, R. J., Berkowitz, J. D., & Burnham, B. S. (2002). Synthesis and cytotoxicity of cyanoborane adducts of n6-benzoyladenine and 6-triphenylphosphonylpurine. Metal-based drugs, 9(1), 19-32. https://doi.org/10.1155/MBD.2002.19
Scarlett, Tanya C, et al. "Synthesis and cytotoxicity of cyanoborane adducts of n6-benzoyladenine and 6-triphenylphosphonylpurine." Metal-based drugs vol. 9,1 (2002): 19-32. doi: https://doi.org/10.1155/MBD.2002.19
Scarlett TC, Durham RW, Hall IH, Crosswicks RJ, Berkowitz JD, Burnham BS. Synthesis and cytotoxicity of cyanoborane adducts of n6-benzoyladenine and 6-triphenylphosphonylpurine. Met Based Drugs. 2002;9(1):19-32. doi: 10.1155/MBD.2002.19. PMID: 18475422; PMCID: PMC2365297.
Copy Download .nbib Format: NLM
DNA minor groove binding ligands: a new class of anticancer agents.

Expert opinion on investigational drugs

D'Incalci M, Sessa C.
PMID: 15989650
Expert Opin Investig Drugs. 1997 Jul;6(7):875-84. doi: 10.1517/13543784.6.7.875.

This paper gives an overview of the available pharmacological and clinical data of a new class of anticancer drugs which act by binding DNA in the minor groove, comprising cyclopropylpyrrolo-indole (CC-1065) derivatives and Distamycin derivatives. The emphasis of this...

Cite
D'Incalci M, Sessa C. DNA minor groove binding ligands: a new class of anticancer agents. Expert Opin Investig Drugs. 1997;6(7):875-84doi: 10.1517/13543784.6.7.875.
D'Incalci, M., & Sessa, C. (1997). DNA minor groove binding ligands: a new class of anticancer agents. Expert opinion on investigational drugs, 6(7), 875-84. https://doi.org/10.1517/13543784.6.7.875
D'Incalci, M, and Sessa, C. "DNA minor groove binding ligands: a new class of anticancer agents." Expert opinion on investigational drugs vol. 6,7 (1997): 875-84. doi: https://doi.org/10.1517/13543784.6.7.875
D'Incalci M, Sessa C. DNA minor groove binding ligands: a new class of anticancer agents. Expert Opin Investig Drugs. 1997 Jul;6(7):875-84. doi: 10.1517/13543784.6.7.875. PMID: 15989650.
Copy Download .nbib Format: NLM
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.

Therapeutics and clinical risk management

Scripture CD, Figg WD, Sparreboom A.
PMID: 18360550
Ther Clin Risk Manag. 2005 Jun;1(2):107-14. doi: 10.2147/tcrm.1.2.107.62910.

Paclitaxel is an anticancer agent effective for the treatment of breast, ovarian, lung, and head and neck cancer. Because of water insolubility, paclitaxel is formulated with the micelle-forming vehicle Cremophor EL to enhance drug solubility. However, the addition of...

Cite
Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag. 2005;1(2):107-14doi: 10.2147/tcrm.1.2.107.62910.
Scripture, C. D., Figg, W. D., & Sparreboom, A. (2005). Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Therapeutics and clinical risk management, 1(2), 107-14. https://doi.org/10.2147/tcrm.1.2.107.62910
Scripture, Charity D, et al. "Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy." Therapeutics and clinical risk management vol. 1,2 (2005): 107-14. doi: https://doi.org/10.2147/tcrm.1.2.107.62910
Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag. 2005 Jun;1(2):107-14. doi: 10.2147/tcrm.1.2.107.62910. PMID: 18360550; PMCID: PMC1661618.
Copy Download .nbib Format: NLM
Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3.

Korean journal of urology

Lee JW, Hong HM, Kwon DD, Pae HO, Jeong HJ.
PMID: 21221209
Korean J Urol. 2010 Dec;51(12):870-8. doi: 10.4111/kju.2010.51.12.870. Epub 2010 Dec 21.

PURPOSE: Curcumin (Cur) has been reported to induce apoptosis in human renal carcinoma Caki cells. Dimethoxycurcumin (DMC), one of several synthetic Cur analogues, has been reported to have increased metabolic stability over Cur. We determined whether DMC, like Cur,...

Cite
Lee JW, Hong HM, Kwon DD, et al. Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean J Urol. 2010;51(12):870-8doi: 10.4111/kju.2010.51.12.870.
Lee, J. W., Hong, H. M., Kwon, D. D., Pae, H. O., & Jeong, H. J. (2010). Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean journal of urology, 51(12), 870-8. https://doi.org/10.4111/kju.2010.51.12.870
Lee, Jea Whan, et al. "Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3." Korean journal of urology vol. 51,12 (2010): 870-8. doi: https://doi.org/10.4111/kju.2010.51.12.870
Lee JW, Hong HM, Kwon DD, Pae HO, Jeong HJ. Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean J Urol. 2010 Dec;51(12):870-8. doi: 10.4111/kju.2010.51.12.870. Epub 2010 Dec 21. PMID: 21221209; PMCID: PMC3016435.
Copy Download .nbib Format: NLM
Alteration of sensitivity to cis-diamine(glycolate)-platinum(II) (254-S) in oral tumor xenografts following multiple applications.

International journal of oncology

Sai S, Kumazawa H, Tachikawa T, Yamashita T, Kawamoto K.
PMID: 21544331
Int J Oncol. 1996 Jan;8(1):57-63. doi: 10.3892/ijo.8.1.57.

The emergence of resistance to platinum analogues is considered to be a major problem in the treatment of head and neck cancer. Therefore, it is important to clarify the mechanisms of resistance to these analogues and the mechanisms of...

Cite
Sai S, Kumazawa H, Tachikawa T, et al. Alteration of sensitivity to cis-diamine(glycolate)-platinum(II) (254-S) in oral tumor xenografts following multiple applications. Int J Oncol. 1996;8(1):57-63doi: 10.3892/ijo.8.1.57.
Sai, S., Kumazawa, H., Tachikawa, T., Yamashita, T., & Kawamoto, K. (1996). Alteration of sensitivity to cis-diamine(glycolate)-platinum(II) (254-S) in oral tumor xenografts following multiple applications. International journal of oncology, 8(1), 57-63. https://doi.org/10.3892/ijo.8.1.57
Sai, S, et al. "Alteration of sensitivity to cis-diamine(glycolate)-platinum(II) (254-S) in oral tumor xenografts following multiple applications." International journal of oncology vol. 8,1 (1996): 57-63. doi: https://doi.org/10.3892/ijo.8.1.57
Sai S, Kumazawa H, Tachikawa T, Yamashita T, Kawamoto K. Alteration of sensitivity to cis-diamine(glycolate)-platinum(II) (254-S) in oral tumor xenografts following multiple applications. Int J Oncol. 1996 Jan;8(1):57-63. doi: 10.3892/ijo.8.1.57. PMID: 21544331.
Copy Download .nbib Format: NLM
Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents.

Oncology reports

Mostafa M, Chalvardjian K, Lami H, Badawi A, Hamzah R.
PMID: 21607420
Oncol Rep. 1994 May;1(3):651-6. doi: 10.3892/or.1.3.651.

The effect of treatment with antineoplastic drugs on the modification of the carcinog en-metabolizing capacity was studied in mice liver microsomes at different durations as a single and as a repeated dose treatment. It is generally demonstrated that there...

Cite
Mostafa M, Chalvardjian K, Lami H, et al. Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents. Oncol Rep. 1994;1(3):651-6doi: 10.3892/or.1.3.651.
Mostafa, M., Chalvardjian, K., Lami, H., Badawi, A., & Hamzah, R. (1994). Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents. Oncology reports, 1(3), 651-6. https://doi.org/10.3892/or.1.3.651
Mostafa, M, et al. "Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents." Oncology reports vol. 1,3 (1994): 651-6. doi: https://doi.org/10.3892/or.1.3.651
Mostafa M, Chalvardjian K, Lami H, Badawi A, Hamzah R. Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents. Oncol Rep. 1994 May;1(3):651-6. doi: 10.3892/or.1.3.651. PMID: 21607420.
Copy Download .nbib Format: NLM
Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.

Hospital pharmacy

Sessink PJ, Trahan J, Coyne JW.
PMID: 24421463
Hosp Pharm. 2013 Mar;48(3):204-12. doi: 10.1310/hpj4803-204.

PURPOSE: In a follow-up to a previous study, surface contamination with the antineoplastic drug cyclophosphamide was compared in 30 US hospital pharmacies from 2004 to 2010 following preparation with standard drug preparation techniques or the PhaSeal closed system drug...

Cite
Sessink PJ, Trahan J, Coyne JW. Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device. Hosp Pharm. 2013;48(3):204-12doi: 10.1310/hpj4803-204.
Sessink, P. J., Trahan, J., & Coyne, J. W. (2013). Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device. Hospital pharmacy, 48(3), 204-12. https://doi.org/10.1310/hpj4803-204
Sessink, Paul J M, et al. "Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device." Hospital pharmacy vol. 48,3 (2013): 204-12. doi: https://doi.org/10.1310/hpj4803-204
Sessink PJ, Trahan J, Coyne JW. Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device. Hosp Pharm. 2013 Mar;48(3):204-12. doi: 10.1310/hpj4803-204. PMID: 24421463; PMCID: PMC3839517.
Copy Download .nbib Format: NLM
Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats.

The Korean journal of hematology

Olufemi AE, Terry AO, Kola OJ.
PMID: 22479280
Korean J Hematol. 2012 Mar;47(1):67-73. doi: 10.5045/kjh.2012.47.1.67. Epub 2012 Mar 28.

BACKGROUND: The use of natural bioactive compounds in conventional chemotherapy is a new direction in cancer treatment that is gaining more research attention recently. Bioactive polysaccharides and polysaccharide-protein complexes from some fungi (edible mushrooms) have been identified as sources...

Cite
Olufemi AE, Terry AO, Kola OJ. Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats. Korean J Hematol. 2012;47(1):67-73doi: 10.5045/kjh.2012.47.1.67.
Olufemi, A. E., Terry, A. O., & Kola, O. J. (2012). Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats. The Korean journal of hematology, 47(1), 67-73. https://doi.org/10.5045/kjh.2012.47.1.67
Olufemi, Akanni E, et al. "Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats." The Korean journal of hematology vol. 47,1 (2012): 67-73. doi: https://doi.org/10.5045/kjh.2012.47.1.67
Olufemi AE, Terry AO, Kola OJ. Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats. Korean J Hematol. 2012 Mar;47(1):67-73. doi: 10.5045/kjh.2012.47.1.67. Epub 2012 Mar 28. PMID: 22479280; PMCID: PMC3317474.
Copy Download .nbib Format: NLM
Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats.

The Korean journal of hematology

Olufemi AE, Terry AO, Kola OJ.
PMID: 22479280
Korean J Hematol. 2012 Mar;47(1):67-73. doi: 10.5045/kjh.2012.47.1.67. Epub 2012 Mar 28.

BACKGROUND: The use of natural bioactive compounds in conventional chemotherapy is a new direction in cancer treatment that is gaining more research attention recently. Bioactive polysaccharides and polysaccharide-protein complexes from some fungi (edible mushrooms) have been identified as sources...

Cite
Olufemi AE, Terry AO, Kola OJ. Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats. Korean J Hematol. 2012;47(1):67-73doi: 10.5045/kjh.2012.47.1.67.
Olufemi, A. E., Terry, A. O., & Kola, O. J. (2012). Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats. The Korean journal of hematology, 47(1), 67-73. https://doi.org/10.5045/kjh.2012.47.1.67
Olufemi, Akanni E, et al. "Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats." The Korean journal of hematology vol. 47,1 (2012): 67-73. doi: https://doi.org/10.5045/kjh.2012.47.1.67
Olufemi AE, Terry AO, Kola OJ. Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats. Korean J Hematol. 2012 Mar;47(1):67-73. doi: 10.5045/kjh.2012.47.1.67. Epub 2012 Mar 28. PMID: 22479280; PMCID: PMC3317474.
Copy Download .nbib Format: NLM
Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?.

Obstetrics and gynecology international

Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos MA, Papadimitriou CA.
PMID: 20148071
Obstet Gynecol Int. 2010;2010:749579. doi: 10.1155/2010/749579. Epub 2010 Feb 02.

Endometrial cancer is the most common gynaecological cancer in western countries. Radiotherapy remains the mainstay of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after staging surgery. The prognosis of patients with metastatic disease...

Cite
Zagouri F, Bozas G, Kafantari E, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?. Obstet Gynecol Int. 2010;2010:749579doi: 10.1155/2010/749579.
Zagouri, F., Bozas, G., Kafantari, E., Tsiatas, M., Nikitas, N., Dimopoulos, M. A., & Papadimitriou, C. A. (2010). Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?. Obstetrics and gynecology international, 2010749579. https://doi.org/10.1155/2010/749579
Zagouri, Flora, et al. "Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?." Obstetrics and gynecology international vol. 2010 (2010): 749579. doi: https://doi.org/10.1155/2010/749579
Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos MA, Papadimitriou CA. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?. Obstet Gynecol Int. 2010;2010:749579. doi: 10.1155/2010/749579. Epub 2010 Feb 02. PMID: 20148071; PMCID: PMC2817540.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 432 entries